185 results about "Enhancer" patented technology

The present disclosure relates to compositions and methods for reducing expression of MYC gene in a cell. In some embodiments, an expression repressor comprises a targeting moiety that binds a MYC promoter, anchor sequence, or super-enhancer. In some embodiments, the expression repressor comprises an effector moiety that represses transcription or methylates DNA. Systems comprising two expression repressors are also disclosed. The compositions can be used, for example, to treat cancers such as HCC.

The invention provides an ELISA (Enzyme Linked Immunosorbent Assay) kit for detecting an anti-MDA5 antibody and a preparation method of the ELISA kit. According to the kit, full-length human MDA5 protein (1025 amino acids) expressed by a cell-free protein expression system under the low-temperature condition of 22 DEG C is adopted as a coating antigen, and a disulfide bond enhancer E6820 is added into the system to promote correct folding of the protein. The kit comprises a microwell plate coated with a full-length MDA5 antigen, an enzyme-labeled anti-human IgG secondary antibody, a standard substance with the concentration range of 1-243 ng / mL, a chromogenic substrate and an optimized confining liquid system. The invention solves the problem of insufficient sensitivity caused by the use of fragment antigens in the prior art, and can be used for early diagnosis and illness monitoring of dermatomyositis-related interstitial lung diseases.

The present invention relates to engineered liver-specific core promoters, synthetic promoters (which contains the engineered core promoters and enhancers), expression vectors (which contains the synthetic promoter), as well as methods of using the promoter or the expression vector thereof to address the need in the field, including treatment of various genetic diseases or conditions associated with the liver. In some embodiments, the liver-specific promoter includes continuous or discontinuous genome sequences from SERPINA1 genome.

The present invention relates to chimeric promoters without CpG motifs. The chimeric promoter comprises a CMV enhancer, an IFN-gamma gene core promoter and an intron sequence, and a CG motif in the CMV enhancer, the IFN-gamma gene core promoter and the intron sequence is subjected to substitution mutation. The promoter can improve the expression efficiency of exogenous genes in activated immune cells.

To provide a method for simply and efficiently evaluating the inducibility of a foreign matter response reaction in the skin of a test sample without using an animal, and to provide a substance having the inhibitory properties of the foreign matter response reaction in the skin and a method for searching the same.SOLUTION: The method includes a step of bringing keratinocytes transformed with a vector having an enhancer sequence containing a foreign body-responsive sequence and a sequence encoding a reporter protein downstream of the enhancer sequence into contact with a solution containing a test sample, a step of measuring the expression level of the reporter protein in the keratinocytes, and a step of evaluating the inducibility of a foreign body response reaction of the test sample in the skin based on the expression level of the reporter protein. The problem is solved by providing an agent for suppressing foreign matter response reaction in the skin containing fregula 1 found by the search method.SELECTED DRAWING: Figure 3

The invention belongs to the technical field of gene engineering, and particularly relates to a medicine for treating AML (acute myelogenous leukemia) and / or prognosis of AML patients and application of ubiquitin specific protease 20 serving as a target spot in treating acute myelogenous leukemia. The invention provides a medicine for treating AML (acute myelogenous leukemia) and / or prognosis of an AML patient and application of ubiquitin specific protease 20 as a target spot in treating acute myelogenous leukemia, USP20 is used as a super enhancer regulation gene, and the progress of the AML is promoted by combining with CTNNB1, ERG, ELF1 and RUNX1. The knock-down of the USP20 can significantly inhibit AML proliferation in vivo and in vitro. The wnt-beta-catenin pathway can be influenced by interfering the expression of the USP20 so as to influence the progress of AML (acute myeloid leukemia). And the inhibition effect of the inhibitor AS1517499 subjected to virtual screening on the growth of the AML cells is superior to that of a commercial inhibitor GSK2643943A of USP20.

Described herein is an oncolytic herpes simplex virus, G47ΔhIL12A, which is G47Δ containing a cassette expressing a transgene, e.g., human IL-12, driven by a spontaneously arising genetically altered HCMV immediate-early (IE) enhancer / promoter. This virus has augmented (A) production of the transgene and increased virus replication while retaining safety. Also provided are methods of use thereof for treating cancer, e.g., glioblastoma (GBM) and triple-negative breast cancer (TNBC).

The present invention relates to an adeno-associated virus (AAV) vector comprising in the 5' to 3' direction: a first AAV2 ITR sequence; a CMV enhancer sequence; a chicken β-actin promoter sequence; a nucleic acid sequence encoding an apolipoprotein 2 (APOE2) polypeptide comprising a Christchurch mutation; a polyA sequence; and a second AAV2 ITR sequence.

The present invention provides methods and compositions for treating cancer in a subject comprising the use of therapeutic cells and compositions to prevent or reduce T cell exhaustion. Modified hematopoietic cells comprising a genomic modification in an enhancer surround the GAB3 gene are also provided.

In one aspect, a method of treating an NK cell to induce a gene edit. The method may include contacting an NK cell with a transfection composition including poly-L-glutamic acid (y- PGA), a single-stranded oligo deoxynucleotide (ssODN) enhancer, or a combination thereof; contacting the NK cell with an editing composition including: a DNA-PK inhibitor, and an HD AC inhibitor; electroporating the NK cell; and contacting the NK cell with a recovery composition including DNase I. In another aspect, a method of preparing an engineered NK cell comprising a fluorescent reporter at an endogenous locus. In another aspect, a method of treating an NK cell to introduce an exogenous nucleic acid.

Disclosed herein is a chimeric nucleic acid including a human telomerase reverse transcriptase (hTERT) enhancer or a fragment thereof and an SV40 enhancer or a fragment thereof and methods of using the same.

A duchenne muscular dystrophy-related exonic splicing enhancer, sgRNA and gene editing tool can be applied in the preparation of drugs for treating duchenne muscular dystrophy. The gene editing tool designed on the basis of cytosine deaminase AID mutants and Cas9 mutants can perform site-specific modification on a mammalian genome by using an adeno-associated virus (AAV) as a vector. By optimizing an encoding nucleic acid sequence and an element composition structure of the editing tool, site-specific targeted modification of mammalian genetic material DNA can be efficiently achieved; and by performing targeted genetic manipulation on the nucleic acid sequence carrying disease mutations, a pathogenic mutation cannot be retained in a mature protein amino acid sequence or the pathogenic mutation cannot perform its function, so that the purpose of treating various gene mutation type genetic rare diseases is achieved, and the advantages of high efficiency, safety and stability are achieved.

The invention belongs to the technical field of gene editing, and particularly relates to a WER10 enhancer and application thereof. The invention provides application of a WER10 nucleic acid molecule and / or a biological material for regulating and controlling the WER10 nucleic acid molecule, the nucleotide sequence of the WER10 nucleic acid molecule is as shown in SEQ ID NO: 1, and the application comprises any one or more of the following items: 1) application of the sequence as shown in SEQ ID NO: 1 as an enhancer; 2) application in enhancing the expression of a downstream reporter gene LUC induced by an immune induction signal; and 3) application in regulation and control of the broad-spectrum antibacterial property of the plants. The sequence and the characteristics of the pathogenic bacterium induced enhancer WER10 located in the intergene region are identified and verified from arabidopsis thaliana, plant immunity related cis-regulatory element resources are enriched, and a new resource is provided for constructing a pathogen induced disease-resistant expression system and developing crop disease-resistant molecular design and breeding.

Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.

Provided is a promoter having high activity in an activated T-cell. The promoter comprises, from 5′-end to 3′-end, a CMV enhancer, an IFNγ promoter, and a long terminal repeat sequence from human T-cell leukemia virus that are connected in sequence. The promoter exhibits greater activity in an activated immune cell than the existing promoters and is low in activity or inactive in other non-immune cells.

The invention relates to the technical field of aquatic animal immune regulation and control, in particular to rHoLL-like stepped lectin-like recombinant protein as well as a preparation method and application thereof. The recombinant protein has pathogen-related molecular pattern recognition and combination capabilities, can promote aggregation of pathogens in a body fluid environment, and activates an aquatic animal complement system, so that the non-specific immune defense capability is enhanced. The preparation method comprises the following steps: amplifying a HoLL-like mature peptide coding sequence, constructing a recombinant expression vector, and converting the recombinant expression vector into an escherichia coli expression host for induced expression to obtain rHoLL-like lectin-like recombinant protein existing in an inclusion body form; and carrying out affinity chromatography purification on the inclusion body protein, and carrying out renaturation treatment in a manner of gradient reduction of denaturant concentration to obtain the rHoLL-like stepped lectin-like recombinant protein. The rHoLL-like stepped lectin-like recombinant protein has good biological safety, and can be applied to aquaculture as an aquatic animal immunopotentiator or a related biological product.

This invention discloses direct amplification qPCR reagents, kits, and applications for whole blood samples. The amplification reagents include: a composite hot-start DNA polymerase system, a buffer system, a surfactant, an anti-contamination system, and an anti-inhibition enhancer system. The composite hot-start DNA polymerase system is obtained by mixing antibody-modified hot-start Taq enzyme and antibody-modified Taq1C2 mutant Taq enzyme in a predetermined ratio. The buffer system includes Tris-HCl, MgCl2, (NH4)2SO4, and KCl. The surfactants include Tween-20 and NP-40. The anti-contamination system includes UDG enzyme and dNTPs, wherein the dNTPs are composed of dATP, dGTP, dCTP, dTTP, and dUTP. The anti-inhibition enhancer system includes D-trehalose, L-carnitine, DMSO, BSA, and SSB single-chain binding protein.

The application discloses a pig 80K functional site gene chip and application thereof, and first designs a gene chip by using pig genome promoter, enhancer, coding region key mutation and the like information, classifies functional sites according to importance based on large-scale multi-omics high-throughput sequencing data, develops a functional site gene chip mainly taking functional sites as the main part, breaks the linkage dependence theory, and solves the problem that the existing commercial chip has poor commonality among different populations due to different linkage degrees among different populations. The chip also has the characteristics of high capture property, low cost and flexibility, and is suitable for commercial application such as pig breed genetic breeding research and selection and matching.

The application provides a non-coding RNA combination for inducing totipotency of mouse embryonic stem cells and application thereof, and relates to the technical field of biology.The combination comprises: an enhancer RNA with a sequence shown as SEQ ID NO:1 or SEQ ID NO:2, and a long-chain non-coding RNA with a sequence shown as SEQ ID NO:3.The application discloses, for the first time, that the CRISPR activation system is used to synergistically up-regulate the expression of the combination, and the conversion of mouse embryonic stem cells to two-cell-like cells can be efficiently promoted.The application does not need to integrate exogenous transcription factors, and thus the risk of genome is avoided; the sgRNA is precisely targeted, and thus the defect of non-specific off-target of chemical small molecules is overcome; a significant synergistic effect is generated, the induction efficiency of two-cell-like cells is significantly improved to about 11.6%, and a new strategy which is safer, more efficient and controllable is provided for stem cell fate reprogramming and early development research.

This invention provides a physiological age prediction model that predicts the physiological age of a subject by detecting urinary proteins and metabolites in a urine sample. The aforementioned urinary proteins and metabolites are those that change significantly with age, including one or more selected from the following: cartilage intermediate layer protein (CILP2), collagen Alpha 1 chain (COFA1), myristic acid, 12-methyltridecanoic acid, CN family member 5 (CCN5), Sushi domain-containing protein 5 (SUSD5), procollagen C endopeptidase enhancer 1 (PCOLCE), and L-lactate oxidase (LOX), preferably including all of the aforementioned urinary proteins and metabolites.

The application provides a kind of regulation IGFBP5 The application belongs to the technical field of gene regulation, and provides an enhancer for regulating the proliferation and adipogenic differentiation of chicken intramuscular preadipocytes, which includes one or more of enhancer EN1, enhancer EN2 and enhancer EN3, the nucleotide sequence of the enhancer EN1 is shown as SEQ ID NO. 2; the nucleotide sequence of the enhancer EN2 is shown as SEQ ID NO. 1; and the nucleotide sequence of the enhancer EN3 is shown as SEQ ID NO. 3. The enhancer can significantly enhance IGFBP5 gene expression and promote the proliferation and adipogenic differentiation of chicken intramuscular preadipocytes.

Provided is a novel use of a composition that contains S-1-propenyl cysteine and / or a salt thereof.　The present invention can be an eNAMPT increasing agent in which S-1-propenyl cysteine or a salt thereof is an active ingredient. The present invention can be an eNAMPT increasing agent that contains S-1-propenyl cysteine or a salt thereof and that is administered to an animal. Particularly, it is preferable that the present invention be used for increasing eNAMPT in blood.

Disclosed herein are synthesis and use of covalent inhibitors selective for Transcriptional Enhancer Factor TEF-1 (TEAD1), which can be used for treatment of cancers such as glioblastoma, gastric cancer, colorectal cancer, pancreatic ductal adenocarcinoma (PDAC), and malignant pleural mesothelioma (MPM). Further disclosed herein are pharmaceutical compositions including the TEAD1 inhibitor and methods of treating cancers using the same.

The invention belongs to the technical field of molecular biology, and provides a reinforcing agent for improving amplification efficiency of mismatched primers in PCR (polymerase chain reaction), a reaction system and application of the reinforcing agent. The reaction system is a liquid reaction system and comprises a reinforcing agent, Trisma, dNTP (deoxyribonucleoside triphosphate), MgCl2, NH4Cl, KCl, BSA (bovine serum albumin), glycerol, betaine, a specific primer, a DNA (deoxyribonucleic acid) template, DNA polymerase, DMSO (dimethylsulfoxide) and water. The invention also provides an application of the enhancer in gene polymorphism detection by a PCR-RFLP (Polymerase Chain Reaction-Restriction Fragment Length Polymorphism) method. Tetramethylammonium chloride and glutathione in the enhancer have a synergistic effect, so that the binding capacity of a mismatched primer and a DNA template can be remarkably enhanced, the completeness of a mismatched region at the 3'end of the primer is protected, and non-specific amplification is inhibited while the amplification efficiency is improved.

A B-cell specific octamer-binding protein 1 super-enhancer ribonucleic acid (BOB1-seRNA) and an application thereof are provided. The nucleotide sequence of the BOB1-seRNA is shown in SEQ ID NO: 1. Through experiments, it further confirms that the BOB1-seRNA is downregulated in patients with coronary heart disease and can be used in preparation of a product for diagnosing or predicting the coronary heart disease. The use of this molecular marker can be used for early diagnosis of the coronary heart disease, which is rapid and effective. It is not only of great significance for early treatment of the coronary heart disease and saving medical costs, but also provides therapeutic targets and important basis for clinical applications such as gene therapy and drug therapy.

To provide nucleic acid molecules targeting a BCL11A enhancer functional region, compositions comprising the nucleic acid molecules, and methods for increasing a fetal hemoglobin level in cells by disrupting BCL11A expression at the genomic level.SOLUTION: Disclosed is a nucleic acid molecule comprising a nucleic acid sequence being: a. complementary to the plus or minus strand of the human chromosome 2 at location 60725424 to 60725688 (+55 functional region); b. complementary to the plus or minus strand of the human second chromosome at location 60722238 to 60722466 (+58 functional region); or c. complementary to the plus or minus strand of the human chromosome 2 at location 60718042 to 60718186 (+62 functional region), where the human chromosome 2 is that according to UCSC Genome Browser hg 19 human genome assembly.SELECTED DRAWING: Figure 3G

The invention discloses a soybean bidirectional promoter, a recombinant vector and a construction method and application thereof, and belongs to the technical field of plant genetic engineering. The soybean bidirectional promoter can simultaneously drive gene expression in two directions, the front end and the rear end of the bidirectional promoter are respectively connected with three genes in series, and simultaneous expression of six genes can be driven by one promoter. The bidirectional promoter is combined with a ZQ6 enhancement sequence and a 35S: MdMYB10 expression cassette, a method for simultaneously and remarkably improving the expression level of more than six genes is developed, and a method for enabling a plant to emit obvious self-luminescence under a dark condition is developed based on the method. The soybean two-way promoter mediated multi-gene efficient synergistic transformation method provided by the invention can be applied to the aspects of constructing a soybean multi-gene synergistic transformation system, realizing rapid polymerization of excellent characters, cultivating new soybean germplasm with excellent characters and the like.

The present application relates to a nucleic acid construct for an insect cell-baculovirus expression system and its application, and belongs to the field of genetic engineering. The present application provides a novel nucleic acid construct, a corresponding insect cell-baculovirus expression system and its application. Specifically, the present application constructs a chimeric promoter capable of efficiently driving the transcription of an exogenous gene by creatively combining a specific enhancer and a promoter and designing the order and direction thereof, and further combines an independent polh promoter to construct a double-promoter system for forming two independent transcription units. The double-promoter system can be placed in the same vector to efficiently drive the expression of the same target gene at different stages of baculovirus infection of insect cells, greatly enhancing the expression intensity and persistence of the target gene at the transcription level, and ultimately improving the yield of the target protein.

The application belongs to the technical field of genetic engineering, and particularly relates to application of TRIM25 gene as a target point in inhibition of H9N2 influenza virus replication.(1) The application finds that inhibition or silencing of the TRIM25 gene can inhibit replication of the H9N2 influenza virus, and TRIM25 can be used as a target point for screening drugs for inhibiting replication of the H9N2 influenza virus;(2) The application provides an sgRNA specifically targeting the TRIM25 gene, and complete knockout of the TRIM25 gene is realized by combining CRISPR-Cas9 technology, and a monoclonal cell line obtained has a resistance phenotype to the H9N2 influenza virus, thereby providing a new idea for prevention and control of the H9N2 influenza virus;(3) The application finds that a TRIM25 cell line with overexpression can promote replication of the H9N2 influenza virus, and TRIM25 or an expression promoter thereof can be used as a replication or production enhancer of the H9N2 influenza virus.